Radiotherapy impact on health-related quality of life in localized prostate cancer: results of an observational, non-interventional, multicenter study in Spain

Almudena Zapatero (almudena.zapatero@salud.madrid.org)
Hospital Universitario de La Princesa

Xavier Maldonado Pijoan
Hospital Universitari Vall d’Hebron

Antonio Gómez-Caamaño
Hospital Clinico Universitario de Santiago de Compostela

José Pardo Masferrer
Hospital Universitari Son Espases

Víctor Macías Hernández
Hospital Universitario de Salamanca

Asunción Hervás Morón
Hospital Ramon y Cajal

Julia Luisa Muñoz García
Hospital Infanta Cristina de Badajoz

Amalia Palacios Eito
Hospital Universitario Reina Sofia

Paloma Anguita-Alonso
Astellas Pharma Inc.

Cristina González-Junco
Astellas Pharma Inc.

José López Torrecilla
ERESA, Hospital General Universitario de Valencia

Research

Keywords: prostate cancer, EPIC, quality-of-life assessment, radiotherapy, brachytherapy, toxicity

DOI: https://doi.org/10.21203/rs.3.rs-208173/v1
Abstract

Background: Health-related quality of life (HRQoL) is greatly affected by prostate cancer (PCa) and associated treatments. This study aimed to measure the impact of radiotherapy on HRQoL and to further validate the Spanish version of the 16-item Expanded Prostate Cancer Index Composite (EPIC-16) in routine clinical practice.

Methods: An observational, non-interventional, multicenter study was conducted in Spain with localized PCa patients initiating treatment with external beam radiotherapy (EBRT) or brachytherapy (BQT). Changes from baseline in EPIC-16, University of California-Los Angeles Prostate Cancer Index (UCLA-PCI), and patient-perceived health status were longitudinally assessed at end of radiotherapy (V2) and 90 days thereafter (V3). Psychometric evaluations of the Spanish EPIC-16 were conducted.

Results: Of 516 patients enrolled, 495 were included in the analysis (EBRT, \(n = 361\); BQT, \(n = 134\)). At baseline, mean (standard deviation [SD]) EPIC-16 global scores were 11.9 (7.5) and 10.3 (7.7) for EBRT and BQT patients, respectively; scores increased, i.e., HRQoL worsened, from baseline, by mean (SD) of 6.8 (7.6) at V2 and 2.4 (7.4) at V3 for EBRT and 4.2 (7.6) and 3.9 (8.2) for BQT patients. Changes in Spanish EPIC-16 domains correlated well with urinary, bowel, and sexual UCLA-PCI domains. EPIC-16 showed good internal consistency (Cronbach’s alpha = .84), reliability, and construct validity.

Conclusion: EPIC-16 scores worsened after radiotherapy in different HRQoL domains, regardless of patient-perceived health status. UCLA-PCI scores mostly recovered for EBRT patients at V3, while scores for BQT patients did not. The Spanish EPIC-16 questionnaire demonstrated sensitivity, strong discriminative properties and reliability, and validity for use in clinical practice.

Background

In Spain, prostate cancer (PCa) is the most common leading type of cancer in terms of incidence and the third most common cause of cancer death in men, with age-standardized incidence and mortality rates of 104.2 and 13.2 per 100,000 men, respectively, in 2018 [1]. There are various treatment options for localized PCa depending on disease stage, including radiotherapy, such as external beam radiotherapy (EBRT) and brachytherapy (BQT) [2]. A recent study showed that for clinically localized PCa in Spain, the majority of patients analyzed (~ 84%) received treatment, with one-third undergoing radiotherapy; ~ 86% were treated with intensity-modulated radiation therapy or 3D radiotherapy and ~ 39% received BQT [3]. However, these therapeutic interventions negatively impact patients in terms of physical and emotional symptoms [4]. Therefore, patient-reported outcome (PRO) measures are increasingly being used to assess long-term health-related quality of life (HRQoL) [5]. A well-established instrument that is frequently used to assess a patient’s post-intervention-related HRQoL is the 50-item Expanded Prostate Cancer Index Composite (EPIC) questionnaire, which was developed based on the University of California-Los Angeles Prostate Cancer Index (UCLA-PCI) [6, 7]. There are two shorter versions of the EPIC-50 questionnaire, the 26-item (EPIC-26) [8] and the 16-item (EPIC-CP) [9] questionnaires; the latter was specifically designed to
be administered in routine clinical practice. EPIC-CP, a one-page questionnaire, measures urinary incontinence, urinary irritation, bowel, sexual, and hormonal HRQoL domains in patients with clinically localized PCA to evaluate aspects of therapy that are most bothersome [9]. The EPIC questionnaire has already been validated and translated in various languages, including Spanish for EPIC-50 [10], Italian for EPIC-26 [11] and German for the shortened EPIC-CP [12].

The primary objective of this study was to measure the impact of radiotherapy on HRQoL. The secondary objectives included further validation and assessment of the measuring properties of the Spanish version of the EPIC-CP questionnaire in routine clinical practice in Spain to enable less time-consuming evaluation of treatment-related HRQoL.

**Methods**

**Study design and participant selection**

This observational, non-interventional, multicenter study was conducted in Spain. Data were collected between January 2016 and September 2017 in 41 radiation oncology departments.

Male patients aged ≥ 40 years with histopathologically confirmed, localized PCA who were initiating EBRT or BQT treatment were included. Patients were required to complete follow-up visit questionnaires. Patients with prior prostatectomy, prior radiotherapy or BQT treatment, or with N1 or metastatic tumor stage were excluded.

The study was approved by the independent ethics committee of participating centers. Patients gave their voluntary informed consent to take part. The decision on treatment was not affected by this study and was solely based on the investigator's criteria.

**Study assessments and data collection**

Patients had three study visits where clinical variables were collected at baseline, i.e., before the beginning of treatment (EBRT or BQT) [visit 1], at the first follow-up visit, i.e., the final EBRT session or 1 month after the first BQT session or seed implantation (visit 2), and a final follow-up visit approximately 3 months after the end of treatment (visit 3).

**Study questionnaires**

Patients completed the following PRO measures at each study visit, with the investigator ensuring all sections were completed properly; the median application time for questionnaires used in this study was not measured. The 16-item EPIC-CP questionnaire, referred to as EPIC-16 in this manuscript, consists of five PCA HRQoL domains and measures urinary, bowel, sexual, vitality, and hormonal health. These five domains contain three questions each with a Likert numeric response scale (NRS) of 0–12 (best to worst
HRQoL) for items 2–10, giving a total NRS of 0–60 (Table 1) [9]. The Spanish version of EPIC-50 by Ferrer, et al. was used to create EPIC-16 used in this study [10].

The UCLA-PCI is a 20-item questionnaire with six domains, with an NRS of 0–100 (worst to best HRQoL) and measures the function and degree of impairment in the urinary, intestinal, and sexual domains (Table 1) [7]. Additionally, patients completed the patient-perceived state of health measure, a one-item questionnaire in which patients evaluated their own general PCa-related health on that day as “Very good”, “Fairly good”, “Slightly good”, “Neither good nor bad”, “Slightly bad”, “Quite bad”, or “Very bad”.

Study objectives

The primary objective was to measure the change in HRQoL between baseline and follow-up visits using EPIC-16 and UCLA-PCI. A secondary objective was to validate the Spanish version of the EPIC-16 questionnaire by analyzing its psychometric properties.

Psychometric validations of the Spanish version of the EPIC-16 questionnaire

The psychometric properties of the EPIC-16 questionnaire were evaluated for feasibility, reliability, construct, and longitudinal validity and sensitivity to change for the total number of patients included in the study at baseline versus the follow-up visits (see Additional file 1).

Statistical analyses

Descriptive statistics were used to summarize patient demographic characteristics, including age, disease stage, and radiotherapy treatment. Standard deviations of the mean values are reported in the figures as error bars either above or below the mean. The correlations between outcomes in EPIC-16 and UCLA-PCI domains were tested using Spearman rank correlation coefficients. Sensitivity to change was assessed using the Student t test for paired data. The questionnaire scores at baseline versus each follow-up visit and scores before and after the type of radiotherapy (EBRT or BQT) were compared using a statistical significance level of .05, which was used for all statistical tests performed.

Results

Patient demographics and baseline characteristics

Overall, 516 patients were enrolled in this study at the baseline visit. Following the second visit, 21 (4.1%) patients were excluded. The remaining 495 patients (95.9%) eligible at visit 3 were included in the analyzed patient population (Fig. 1). A total of 361 patients (72.9%) received EBRT and 134 patients (27.1%) received BQT treatment.
Baseline characteristics stratified by EBRT or BQT treatment groups are summarized in Table 2. At baseline, median patient age (range) was 73.0 (48.0–84.0) years and 67.0 (48.0–82.0) years for the EBRT and BQT groups, respectively. Most patients who received EBRT had a Gleason score of ≥ 7 (73.1%), while most patients who received BQT had a Gleason score of < 7 (84.3%). A higher proportion of patients received neo-adjuvant hormone therapy in the EBRT group (62.0%) than in the BQT group (6.0%) [Table 2].

At baseline, the total EPIC-16 mean (standard deviation [SD]) scores were 11.9 (7.5) and 10.3 (7.7) for the EBRT and BQT groups, respectively (see Supplementary Fig. 1A, Additional file 1) and the UCLA-PCI mean (SD) scores ranged from 27.0 (26.8) to 90.1 (21.5) and 42.2 (30.5) to 90.3 (23.0) across the domains for the EBRT and BQT groups, respectively (see Supplementary Fig. 1B, Additional file 1).

**Impact of radiotherapy on quality of life (QoL)**

EPIC-16 total scores increased by a mean (SD) of 6.8 (7.6) points at visit 2 and by 2.4 (7.4) points at visit 3 for patients in the EBRT group. For patients who received BQT, the scores increased by a mean (SD) of 4.2 (7.6) and 3.9 (8.2) points at visits 2 and 3, respectively.

Overall, scores increased after radiotherapy, indicating a worsened QoL, across all EPIC-16 domains (Fig. 2). At visit 3 particularly, patients recovered their baseline scores in the urinary incontinence, bowel, vitality/hormonal, and urinary irritation domains, with the exception of the bowel and urinary irritation domains in patients receiving BQT (Fig. 2B and Fig. 2C). The sexual domain scores of patients in both groups worsened at both time points and did not recover at visit 3 compared to other domains. Patients who received concomitant hormone therapy, initiated prior to either EBRT or BQT, showed a higher mean score in the sexual domain between study visits 1 and 2 (mean [SD] visit 1: 6.79 [3.16]; mean [SD] visit 2: 8.39 [2.52]) than patients without hormone therapy (mean [SD] visit 1: 4.84 [3.45]; mean [SD] visit 2: 6.15 [3.29]).

For the overall evolution of urinary problems, e.g., item 1 of EPIC-16 (“Overall, how much of a problem has your function been for you?”), responses were similar at baseline for both EBRT and BQT patients (see Supplementary Fig. 2, Additional file 1). However, more patients treated with EBRT increasingly perceived urinary function as a small-to-big problem at visit 2 (62.0%, n = 221) compared with patients treated with BQT (53.2%, n = 67). At visit 3, patients’ perceptions returned to baseline, i.e., with urinary condition perceived as less of a problem compared with visit 2 (small-to-big problem: 35.5%, n = 126 for EBRT; 48.5%, n = 65 for BQT) [see Supplementary Fig. 2, Additional file 1].

Similarly, for patients who received EBRT, all UCLA-PCI scores showed a decrease at visit 2, indicating worsened QoL, especially in urinary bother, bowel function and bother, and sexual function domains (Fig. 3). At visit 3, scores had recovered QoL in the urinary function, urinary bother, and bowel function domains. For patients who received BQT, UCLA-PCI scores were decreased at visit 2 in the urinary bother, bowel bother, and sexual function domains, none of which recovered at visit 3 (Fig. 3).
Validation of the Spanish version of the EPIC-16 questionnaire

Psychometric validation of the EPIC-16 questionnaire was conducted in 484 patients (EBRT, \( n = 357 \); BQT, \( n = 127 \)).

Reliability of EPIC-16

A strong internal consistency of the Spanish EPIC-16 questionnaire was demonstrated in the vitality/hormonal (Cronbach's alpha = .729 [95% confidence interval (CI) .68–.77]), urinary incontinence (Cronbach's alpha = .735 [95% CI .69–.77]), urinary irritation (Cronbach's alpha = .777 [95% CI .74–.81]), and bowel function domains (Cronbach's alpha = .879 [95% CI .86–.90]). Only the sexual function domain was < .7 (Cronbach's alpha = .616 [95% CI .56–.66]).

Test–retest reliability intraclass correlation coefficient (ICC) was analyzed for 226 patients who did not perceive any change in their health status (according to the patient-perceived state of health measure) after radiotherapy. The ICC was moderate in all domains (range, .52–.66), with the exception of the bowel function domain (ICC = .232 [95% CI .10–.36]), indicating that reproducibility in this domain cannot be ensured.

Feasibility of EPIC-16

The floor effect, i.e., worst score of 12 for each domain, was present in < 1% of patients, with the exception of the sexual domain for which 24 (4.9%) patients had a maximum score of 12 at baseline, which increased to 44 (9.1%) and 56 (11.5%) patients at visits 2 and 3, respectively (see Supplementary Fig. 3, Additional file 1).

The ceiling effect, i.e., best score of 0 for each domain, was reached by a high percentage of men in urinary incontinence (\( n = 364; 65.6\% \)), bowel (\( n = 345; 70.1\% \)), and vitality/hormonal function (\( n = 223; 45.5\% \)) domains at baseline (see Supplementary Fig. 3, Additional file 1). Generally, responses were maintained for most items during radiotherapy treatment; while some decreased at study visit 2, they recovered to baseline scores at visit 3. Only items related to sexual domain (7, 8, and 9) showed a greater number of problems and worsened after radiotherapy (see Supplementary Fig. 3, Additional file 1).

Construct validity of EPIC-16

Correlations between different EPIC-16 domains were modest (\( r < .50 \) for all Spearman's correlations at baseline), indicating that the EPIC-16 domains are conceptually distinct and merit independent measure (see Supplementary Table 1, Additional file 1).
**EPIC-16 sensitivity to change**

Compared to baseline, almost all EPIC-16 mean domain scores worsened at visit 2, regardless of the health-state change as perceived by the patient; similar results were reported at visit 3, with the exception of the urinary irritation/obstruction domain which improved (Fig. 4).

Patients who reported an improved health status at visit 2 compared with baseline generally had smaller effect sizes (i.e., .20 in magnitude) versus those who reported a worsened health status; similar results were also reported at visit 3 (Fig. 4).

**Correlation between EPIC-16 and UCLA-PCI**

Overall, the EPIC-16 questionnaire scores showed strong correlations with the UCLA-PCI questionnaire domains at study visit 3, with Spearman’s correlations > .4 across all corresponding UCLA-PCI domains (Table 3). The urinary, bowel, and sexual function domains in the EPIC-16 questionnaire were most greatly correlated with respective domains in the UCLA-PCI questionnaire, e.g., the UCLA-PCI urinary function domain had a Spearman’s correlation coefficient with the EPIC-16 urinary incontinence domain of .713, the bowel domains with .579, and the sexual domains with .739.

**Discussion**

This observational, non-interventional, multicenter study in Spain measured the change in HRQoL in men with localized PCa undergoing radiotherapy using the EPIC-16 and UCLA-PCI questionnaires, and further validated the Spanish EPIC-16 for routine clinical practice. Overall, EPIC-16 scores worsened after radiotherapy in different HRQoL domains, regardless of patients’ perceptions of their health status, suggesting that patients did not perceive the change in functional domains as a global change in their health status. Similarly, the UCLA-PCI scores decreased with radiotherapy in both treatment groups (EBRT or BQT). However, 3 months after the end of radiotherapy, EBRT patients had recovered their scores in the urinary function, urinary bother, and bowel function domains. Conversely, BQT patients did not recover in urinary bother, bowel bother, and sexual function domains.

Similarly, in a long-term prospective QoL study in patients with localized PCa using EPIC-50, Ferrer, et al. reported that BQT treatment caused the least impact on QoL, except for moderate urinary irritative-obstructive symptoms, while sexual deterioration was observed for patients receiving EBRT [13].

The UCLA-PCI baseline values presented in this study were very similar to those reported by van de Poll-Franse, et al. in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study, although the post-treatment scores of this study were smaller in magnitude compared to those of the CaPSURE study, which is likely due to the shorter period for the follow-up visits in this study (3 months) versus the 6–24-month follow-up period of CaPSURE [14].
Additionally, validation of the EPIC-16 questionnaire results obtained in this study was similar to results obtained by a number of EPIC-CP validation studies, especially those at study visit 2 [9, 15]. However, differences exist in the sexual and vitality/hormonal domains between these studies, which may be due to differences in use of concomitant hormone therapy [15, 16].

Even though the EPIC questionnaires were developed from UCLA-PCI [6, 7], both instruments were used in this study to further assess the validity of the Spanish version of the EPIC-16 questionnaire. The previous EPIC-CP study by Chang, et al. [9] was validated in a smaller study cohort (N = 307) compared to this study, with 175 treated and 132 untreated patients. Furthermore, the current study also included evaluation of longitudinal validity, in addition to correlational analysis between EPIC-16 and UCLA-PCI domains. Hence, the results presented here further add to these previously reported results for the English EPIC-CP.

The results of the current study further highlight the importance of using appropriate PRO instruments to aid physicians treating patients newly diagnosed with localized PCa, enabling them to decide appropriate treatment strategies, to consider their potential adverse effects, and to incorporate individual patient preferences [17-21].

This study showed that the Spanish version of the EPIC-16 questionnaire demonstrated sensitivity to detect both PCa treatment-related effects and sensitivity for clinical improvement after radiotherapy. Furthermore, it was also shown that EPIC-16 has strong discriminative properties and reliability, demonstrating its validity for use in clinical practice and clinical trials to evaluate the effect of interventions, further expanding similar results obtained by Balbontin, et al. from a smaller patient population [22]. The EPIC-16 domains showed correlations with the respective functional domains in the UCLA-PCI questionnaire. Although these results show that both questionnaires are highly correlated in the urinary, bowel, and sexual function domains, they do not measure exactly the same information and are therefore complementary.

In future, the validated Spanish EPIC-16 could be utilized in a larger-scale analysis with more longitudinal components to further assess PROs comparing different types of radiation therapies, similar to what has been recently done for EPIC-26 by Nossiter, et al [23].

A main limitation of this study was its observational design. In addition, the smaller-than-planned sample for the BQT group affected the power of the hypothesis testing and resulted in large CIs and lack of statistical significance. It should be noted that the changes seen in BQT patients are not permanent; these patients were still on treatment due to the nature of the therapy. Additionally, the use of neo-adjuvant and concomitant hormone therapy might impact data concerning sexual function [16]. Higher use of neo-adjuvant/androgen deprivation therapy in patients treated with EBRT versus those treated with BQT is a limitation for the interpretation of results and may have impacted differences observed in the sexual and hormonal/vitality domains, as reported previously [24]. Furthermore, despite several studies having suggested that neo-adjuvant/androgen deprivation therapy in addition to RT increased the incidence of urinary or rectal toxicity [25], other studies have not corroborated these findings [26, 27].
Conclusions

In this observational study conducted in Spain, men with localized PCa undergoing radiotherapy reported worsened scores in different HRQoL domains of the EPIC-16 and UCLA-PCI questionnaires immediately after radiotherapy treatment; however, a strong tendency towards recovery was seen at the 3-month follow-up visit. Regardless, patients did not perceive a global HRQoL change. Validation of the Spanish version of the EPIC-16 demonstrated sensitivity, strong discriminative properties and reliability, and validity. This shortened questionnaire is therefore suitable for use in routine clinical practice in Spain to measure urological HRQoL in this population.

Declarations

Ethics approval and consent to participate

The study was approved by the independent ethics committee of participating centers. Patients gave their voluntary informed consent to take part.

Consent for publication

Not applicable.

Availability of data and materials

Researchers may request access to anonymized participant-level data, trial-level data, and protocols from Astellas sponsored clinical trials at www.clinicalstudydatarequest.com. For the Astellas criteria on data sharing, see: https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Astellas.aspx.

Competing interests

AZ has received grants from Astellas during the conduct of the study and has received lecture fees from Astellas and Janssen and travel grants from IPSEN. XMP has received lecture fees from Astellas and Bayer and travel grants from IPSEN and Sanofi. AHM is a speaker and research collaborator for Astellas and Janssen. AGC and JLT report collaborations with Astellas for the current study. JPM, VMH, JLMG, and APE were investigators in this Astellas-sponsored study. PAA and CGJ are employees of Astellas.

Funding

This study was funded by Astellas Pharma Inc.
Authors' contributions

The authors' contributions have been as follows:

Conception or design: all authors.

Acquisition, analysis, or interpretation of the data: all authors.

Creation of new software used in the work: N/A

Drafted the work or substantively revised it: all authors.

All authors approved the final manuscript for submission and agreed to be personally accountable for their own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Acknowledgments

Medical writing assistance was provided by Beatrice Vetter-Ceriotti, PhD, and editorial assistance was provided by Lauren Smith of Complete HealthVizion, both funded by Astellas Pharma Inc.

The authors would also like to acknowledge the investigators who recruited patients into the study; the full list is provided in Additional file 1.

Abbreviations

BQT: Brachytherapy; CaPSURE: Cancer of the Prostate Strategic Urologic Research Endeavor; CI: Confidence interval; EBRT: External beam radiotherapy; EPIC: Expanded Prostate Cancer Index Composite; HRQoL: Health-related quality of life; ICC: Intraclass correlation coefficient; NRS: Numeric response scale; PCa: Prostate cancer; PRO: Patient-reported outcome; QoL: Quality of life; SD: Standard deviation; UCLA-PCI: University of California-Los Angeles Prostate Cancer Index

References

1. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018, 103:356-387.

2. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossa N, Gross T, Henry AM, Joniau S, et al: EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017, 71:618-629.

3. Gómez-Veiga F, Rodríguez-Antolín A, Miñana B, Hernández C, Suárez JF, Fernández-Gómez JM, Unda M, Burgos J, Alcaraz A, Rodríguez P, et al: Diagnosis and treatment for clinically localized prostate
cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study - GESCAP group. *Actas Urol Esp* 2017, **41:**359-367.

4. Bill-Axelson A, Garmo H, Holmberg L, Johansson JE, Adami HO, Steineck G, Johansson E, Rider JR: Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. *Eur Urol* 2013, **64:**920-928.

5. Protopapa E, van der Meulen J, Moore CM, Smith SC: Patient-reported outcome (PRO) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments. *BJU Int* 2017, **120:**468-481.

6. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG: Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. *Urology* 2000, **56:**899-905.

7. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH: The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. *Med Care* 1998, **36:**1002-1012.

8. Szymanski KM, Wei JT, Dunn RL, Sanda MG: Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. *Urology* 2010, **76:**1245-1250.

9. Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, DeWolf WC, et al: Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. *J Urol* 2011, **186:**865-872.

10. Ferrer M, Garin O, Pera J, Prats JM, Mendivil J, Alonso J, De Paula B, Herruzo I, Hervas A, Macias V, et al: Evaluation of the quality of life of patients with localized prostate cancer: validation of the Spanish version of the EPIC. *Med Clin (Barc)* 2009, **132:**128-135.

11. Marzorati C, Monzani D, Mazzocco K, Masiero M, Pavan F, Monturano M, Pravettoni G: Validation of the Italian version of the abbreviated expanded prostate Cancer index composite (EPIC-26) in men with prostate Cancer. *Health Qual Life Outcomes* 2019, **17:**147.

12. Umbehr MH, Bachmann LM, Poyet C, Hammerer P, Steurer J, Puhan MA, Frei A: The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation. *Health Qual Life Outcomes* 2018, **16:**36.

13. Ferrer M, Guede F, Suárez JF, de Paula B, Macías V, Mariño A, Hervás A, Herruzo I, Ortiz MJ, Ponce de León J, et al: Quality of life impact of treatments for localized prostate cancer: cohort study with a 5 year follow-up. *Radiother Oncol* 2013, **108:**306-313.

14. van de Poll-Franse LV, Sadetsky N, Kwan L, Litwin MS: Severity of cardiovascular disease and health-related quality of life in men with prostate cancer: a longitudinal analysis from CaPSURE. *Qual Life Res* 2008, **17:**845-855.
15. Chipman JJ, Sanda MG, Dunn RL, Wei JT, Litwin MS, Crociani CM, Regan MM, Chang P: Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. *J Urol* 2014, **191**:638-645.

16. Gay HA, Sanda MG, Liu J, Wu N, Hamstra DA, Wei JT, Dunn RL, Klein EA, Sandler HM, Saigal CS, et al: External beam radiation therapy or brachytherapy with or without short-course neoadjuvant androgen deprivation therapy: Results of a multicenter, prospective study of quality of life. *Int J Radiat Oncol Biol Phys* 2017, **98**:304-317.

17. Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T, Cornford P, Cumberbatch MG, Fossati N, Gross T, et al: Quality of life outcomes after primary treatment for clinically localised prostate cancer: A systematic review. *Eur Urol* 2017, **72**:869-885.

18. Sureda A, Fumadó L, Ferrer M, Garín O, Bonet X, Castells M, Mir MC, Abascal JM, Vigués F, Cecchini L, Suárez JF: Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study. *Health Qual Life Outcomes* 2019, **17**:11.

19. O'Callaghan ME, Raymond E, Campbell JM, Vincent AD, Beckmann K, Roder D, Evans S, McNeil J, Millar J, Zalcberg J, et al: Patient-reported outcomes after radiation therapy in men with prostate cancer: A systematic review of prognostic tool accuracy and validity. *Int J Radiat Oncol Biol Phys* 2017, **98**:318-337.

20. Chen RC, Basak R, Meyer AM, Kuo TM, Carpenter WR, Agans RP, Broughman JR, Reeve BB, Nielsen ME, Usinger DS, et al: Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. *JAMA* 2017, **317**:1141-1150.

21. Zelefsky MJ, Poon BY, Eastham J, Vickers A, Pei X, Scardino PT: Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer. *Radiother Oncol* 2016, **118**:85-91.

22. Balbontín F, Marchetti P, Moreno S, Cabello JM, Urzúa C, Silva A, Avilés J, Badínez L, García J, Salgado A, et al: [Quality of life in patients with prostate cancer: validation of an instrument for clinical practice]. *Arch Esp Urol* 2015, **68**:466-473.

23. Nossiter J, Sujenthiran A, Cowling TE, Parry MG, Charman SC, Cathcart P, Clarke NW, Payne H, van der Meulen J, Aggarwal A: Patient-reported functional outcomes after hypofractionated or conventionally fractionated radiation for prostate cancer: A national cohort study in England. *J Clin Oncol* 2020, **38**:744-752.

24. Dearnaley DP, Saltzstein DR, Sylvester JE, Karsh L, Mehlhaff BA, Pieczonka C, Bailen JL, Shi H, Ye Z, Faessel HM, et al: The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomised, open-label, parallel-group phase 2 trial. *Eur Urol* 2020, doi: 10.1016/j.eururo.2020.03.001.
25. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003, 21:3972-3978.

26. Lawton CA, Bae K, Pilepich M, Hanks G, Shipley W: Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int J Radiat Oncol Biol Phys 2008, 70:437-441.

27. Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, Pinnarò P, Terzoli E, Cognetti F, Carlini P: Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. Cancer 2009, 115:3446-3456.

28. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA: The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2016, 40:244-252.

Tables

Table 1 EPIC-16 and UCLA-PCI domains and response scales

| Instrument       | EPIC-16                           | UCLA-PCI                    |
|------------------|-----------------------------------|-----------------------------|
| Domains          | Urinary incontinence              | Urinary function            |
|                  | Urinary irritation/obstruction     | Urinary bother              |
|                  | Bowel function                     | Bowel function              |
|                  | Sexual function                    | Bowel bother                |
|                  | Vitality/hormonal function         | Sexual function             |
|                  |                                    | Sexual bother               |
| NRS range, points| Domain score 0–12                  | 0–100                       |
|                  | Total score 0–60 (best to worst HRQoL) | 0–100 (worst to best HRQoL) |

Table 2 Baseline demographics and disease characteristics
Analyzed patients \((n = 495)\)

| Demographics and disease characteristics | EBRT \((n = 361)\) | BQT \((n = 134)\) |
|------------------------------------------|-------------------|------------------|
| Median age, years (range) | 73.0 (48.0–84.0) | 67.0 (48.0–82.0) |
| Gleason score (grouped), \(a n (%)\) | | |
| Grade group 1 | 97 (26.9) | 113 (84.3) |
| Grade group 2 | 94 (26.0) | 21 (15.7) |
| Grade group 3 | 74 (20.5) | 0 |
| Grade group 4 | 55 (15.2) | 0 |
| Grade group 5 | 41 (11.4) | 0 |
| Median prostate-specific antigen at diagnosis, ng/mL (range) | 8.1 (1.7–342.0) | 5.9 (1.0–15.7) |
| Median prostate-specific antigen at initial EBRT/BQT, ng/mL (range) | 3.5 (.0–100.0) | 5.8 (.8–17.2) |
| Median testosterone at initial EBRT/BQT, ng/dL (range) | \(n = 177\) 10.0 (.0–913.0) | \(n = 21\) 291.0 (2.6–619.6) |
| TNM stage at initial EBRT/BQT, \(n (%)\) | | |
| T1c | 104 (28.8) | 91 (67.9) |
| T2 | 148 (41.0) | 19 (14.2) |
| T3 | 68 (18.8) | 0 |
| Eastern Cooperative Oncology Group performance status at initial EBRT/BQT, \(n (%)\) | | |
| 0 | 314 (92.1) | 125 (96.2) |
| 1 | 23 (6.7) | 5 (3.8) |
| 2 | 4 (1.2) | 0 |
| Not available | 20 | 4 |
| Type of BQT, \(n (%)\) | NA | |
| Low-dose BQT/seed | 118 (88.1) | |
| High-dose BQT | 16 (11.9) | |
| Location of EBRT treatment, \(n (%)\) | NA | |
| Prostate | 361 (100) | |
| Lymph nodes | 94 (26.0) | |
|                      |        |
|----------------------|--------|
| Seminal vesicles     | 280 (77.6) |
| **Type of EBRT treatment,\(^{b}\) n (%)** |        |
| 3D CRT               | 104 (29.1) |
| IMRT or VMAT         | 254 (70.9) |
| **Neo-adjuvant hormone treatment, n (%)** |        |
| Prior to EBRT/BQT    | 224 (62.0) |
| Initiating EBRT/BQT  | 219 (97.8) |
|                      | 5 (2.2) |
| **Previous interventions, n (%)** |        |
| Yes                  | 141 (39.1) |
| No                   | 213 (59.0) |
| Unknown              | 7 (1.9) |
| **Previous surgery, n (%)** |        |
| TURP                 | 39 (10.8) |
|                      | 8 (6.0) |

\(^{a}\)Grade group 1 = Gleason score ≤ 6; Grade group 2 = Gleason score 3+4 = 7; Grade group 3 = Gleason score 4+3 = 7; Grade group 4 = Gleason score 8; Grade group 5 = Gleason scores 9 and 10 [28]. \(^{b}\)Of patients who received EBRT treatment of the prostate \((n = 358)\)

3D CRT Three-dimensional conformal radiation therapy, IMRT Intensity-modulated radiation therapy, NA Not available, TNM Tumor, node, metastasis, TURP Transurethral resection of the prostate, VMAT Volumetric-modulated arc therapy

**Table 3** Correlation between EPIC-16 and UCLA-PCI scores at study visit 3
| EPIC-16 domains       | UCLA-PCI domains                      |                |                |
|-----------------------|---------------------------------------|----------------|----------------|
|                       |                                       | Urinary function | Bowel function | Sexual function |
| Urinary incontinence  | -.713                                 | -.247          | -.146          |
| Urinary irritation/obstruction | -.468             | -.301          | -.065          |
| Bowel                 | -.355                                 | -.579          | -.009          |
| Sexual                | -.152                                 | -.094          | -.739          |
| Vitality/hormonal     | -.254                                 | -.314          | -.210          |
| Total score           | -.509                                 | -.429          | -.443          |

All data are Spearman’s correlation coefficients